A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1

Trial Profile

A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2018

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DESTINY-Breast01
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 11 Jun 2018 According to data presented at the 54th Annual Meeting of the American Society of Clinical Oncology, 35 (planned 230 subjects) have been enrolled as of Feb. 12, 2018.
    • 05 Jun 2018 Study design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 19 Oct 2017 Planned End Date changed from 1 Aug 2019 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top